David Safley, MD
Interventional Cardiology · Kansas City, MONPI 1831147420
Payments from drug & device makers
Across 86 payments — averaging $89.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- Medtronic$2K
- Boston Scientific$1K
- Shockwave Medical, Inc$373
- Edwards Lifesciences$204
- Osprey Medical Inc$175
- plus $270 from 3 others
What the payments were for
- Travel & lodging$1,31117%
- Food & beverage$6,39583%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 46 | $4,084 |
| Medtronic(2 entities) | 16 | $1,588 |
| Boston Scientific | 12 | $1,025 |
| Shockwave Medical, Inc | 5 | $373 |
| Edwards Lifesciences | 2 | $204 |
| Osprey Medical Inc | 2 | $175 |
| Livanova USA, Inc. | 1 | $131 |
| Cardiva Medical, Inc. | 1 | $126 |
| Chiesi USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PERCLOSE PROGLIDE$1,776
- RESOLUTE ONYX$683
- ESPRIT$312
- AVVIGO Guidance System$234
- Edwards SAPIEN 3 Transcatheter Heart Valve$184
- Xience V coronary stent system$162
- ONYX FRONTIER$157
- COROFLOW$154
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$153
- DyeVert$149
- Optis Coronary Imaging System$147
- OPTICROSS$143
- TandemLife$131
- OPTIS$131
- Cardiva VASCADE 6/7F VCS$126
- GENERAL ATHERECTOMY$114
- GENERAL - THERAPIES$109
- Resolute$100
How this compares
$7,718 in reported general payments places this provider in the 35th percentile of 182 interventional cardiology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 80 | $104,580 |
| Repatha SureclickEvolocumab | 25 | $29,348 |
| XareltoRivaroxaban | 17 | $27,507 |
| VascepaIcosapent Ethyl | 12 | $4,000 |
| Metoprolol Succinate | 121 | $2,318 |
| Ezetimibe | 72 | $2,271 |
| Rosuvastatin Calcium | 82 | $1,289 |
| Atorvastatin Calcium | 144 | $1,224 |
| ClopidogrelClopidogrel Bisulfate | 76 | $1,005 |
| Carvedilol | 93 | $997 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 34 | $818 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 49 | $654 |
| Valsartan | 12 | $651 |
| Lisinopril | 76 | $538 |
| Cilostazol | 22 | $491 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Kansas City
- Adnan ChhatriwallaKansas City$3.6M
- James GranthamKansas City$1.6M
- Steven MarsoKansas City$921K
- Matthew BunteKansas City$618K
- Steven LasterKansas City$571K
- Chetan HudedKansas City$513K
- Gerald MancusoKansas City$402K
- Kenneth HuberKansas City$279K
- Adam SalisburyKansas City$265K
- Anthony HartKansas City$202K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.